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Fibrinogen is the key substrate of thrombin in haemostatic clot
formation, and its plasma concentration is highly susceptible to
blood loss andhaemodiluton;1–3 therefore, it has been recognized
as a primary target of coagulation therapy in themanagement of
perioperative major bleeding.2–7 Human plasma-derived ﬁbrino-
gen concentrate is convenient to use because it is lyophilized and
quickly reconstituted for i.v. injection. In addition, it is simple to
monitor the dose because ﬁbrinogen concentrate increases plas-
ma ﬁbrinogen concentration in a dose-dependent manner8 and
increases ﬁbrin-speciﬁc clot formation (FIBTEM) on thromboelas-
tometry.9 10 However, there is no consensus on the minimal
ﬁbrinogen concentration or FIBTEM value that is required for
perioperative haemostasis,11 and there are concerns regarding
overuse and misuse.12 13 The value of FIBTEM-based ﬁbrinogen
interventions has been evaluated previously in both prospective
studies and retrospective analyses (Table 1).14 17–19 However, it
is yet unknown whether a low normal ﬁbrinogen concentration
(1.5 g litre−1) is adequate for haemostasis in the perioperative
setting or whether higher concentrations of ﬁbrinogen might be
required to reduce bleeding.
In this issue of the British Journal of Anaesthesia, Haas and
colleagues15 shed new light on the perioperative ﬁbrinogen re-
placement strategy. The authors performed a well-designed ran-
domized controlled study in paediatric patients undergoing
craniosynostosis and scoliosis surgery. Patients were rando-
mized to receive therapy with ﬁbrinogen concentrate based on
a high (13 mm) or low target value (8 mm) of FIBTEM maximal
clot ﬁrmness (MCF). The authors found that intraoperative
ﬁbrinogen intervention using the higher threshold signiﬁcantly
reduced bleeding by∼67% and transfusion requirements by near-
ly 50% compared with the lower threshold value in craniosynos-
tosis surgery. In scoliosis surgery, however, the extent of bleeding
was similar between both groups, and only a trend for reduced
transfusion with the higher threshold was found.
The two thresholds, 8 and 13mm of FIBTEMMCF, used in this
study represent the lower and upper target range in the European
guidelines for the treatment of massive perioperative bleeding.6
They are also likely to correspond to the minimal ﬁbrinogen
concentration (1.5 g litre−1) recommended by the European
guidelines6 and the median concentration of ﬁbrinogen (2.35 g
litre−1) for this age group.20 Those who were randomized to the
higher threshold received intervention early because their
baseline FIBTEM MCF values were 10–11 mm (corresponding to
plasma concentrations of about 1.8–2.0 g litre−1).21 It can be
speculated that plasma ﬁbrinogen concentrations were main-
tained at above 2.0 g litre−1 in the high-threshold group when
intraoperative bleeding occurred. In the low-threshold group,
however, plasma ﬁbrinogen could be decreased to below 1.5 g
litre−1 as bleeding continued. It is thus important to consider
the timing of therapy in addition to the optimal threshold.
Nakayama and colleagues16 recently reported a prospective ran-
domized study of conventional vs thromboelastometry-guided
haemostatic intervention in paediatric cardiac surgery. In their
study, the FIBTEM threshold was set rather low at 5 mm for
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Table 1 Fibrin-speciﬁc clot formation thresholds used by published prospective randomized studies.A10/15, amplitude after 10/15min; ACT, activated clotting time; FC, ﬁbrinogen concentrate; FFP,
fresh frozen plasma; FIBTEM, ﬁbrin-speciﬁc clot formation; MCF, maximal clot formation; NA, not available; RBC, red blood cell; ROTEM, rotational thromboelastometry
Author, yr Study setting Intervention and trigger values Key ﬁndings Fibrinogen concentrations
after surgeryIntervention group Control group
Girdauskas and
colleagues, 201014
56 adult patients undergoing
complex cardiac surgery
FC administered if FIBTEM
MCF<8 mm (n=27)
FC administered if plasma
ﬁbrinogen concentration
<1.2 g litre−1 (n=29)
ROTEM-guided transfusion is
associated with decreased





49 paediatric patients undergoing
craniosynostosis or scoliosis
surgery
FC administered if FIBTEM
MCF<13 mm (n=27)
FC administered if FIBTEM
MCF<8 mm (n=22)














protamine 0.5 mg kg−1
(n=50)
ROTEM-guided transfusion
reduced bleeding and RBC
transfusion
1.65 g litre−1 (intervention)
vs 1.25 g litre−1 (control)
Rahe-Meyer and
colleagues, 20137
61 bleeding adult patients
undergoing complex cardiac
surgery





FC reduced the need for
allogeneic blood products
2.60 g litre−1 (intervention)
vs 1.89 g litre−1 (control)
Weber and colleagues,
201217
100 bleeding adult patients
undergoing cardiac surgery
FC administered if FIBTEM
A10≤10 mm (n=50)
FC administered if plasma
ﬁbrinogen concentration





2.29 g litre−1 (intervention)






10 min amplitude (A10), but the FIBTEM-based protocol resulted
in early plasma transfusion compared with the conventional
therapy. The reduced red blood cell transfusion and post-
operative blood loss in the FIBTEM group are partly explained
by the higher ﬁbrinogen concentrations than thosewith the con-
ventional therapy (1.65 vs 1.25 g litre−1). Importantly, total
amounts of plasma and platelet transfusion were not different
between both groups.16 Likewise, Haas and colleagues15 found
that total administered amounts of ﬁbrinogen and factor XIII
concentrate, and of plasma and platelet transfusion were com-
parable between their two groups. It is thus important to opti-
mize the threshold and the timing of haemostatic intervention
because they interact closely with each other.
There have been previous clinical studies that involved
prophylactic administration of ﬁbrinogen concentrate to main-
tain high normal ﬁbrinogen concentrations for cardiac surgery22
and for postpartumhaemorrhage.23 However,major concerns re-
garding the prophylactic substitution are that bleeding attribut-
able to a surgical cause cannot be stopped by ﬁbrinogen, and
administered ﬁbrinogen can quickly be lost in haemorrhage
andhaemodilution.24 The efﬁcacyof prophylactic ﬁbrinogen sub-
stitution may be strongly inﬂuenced by the surgical technique,
extent of vascular injury, and intraoperative blood loss. The
study by Haas and colleagues15 was, therefore, terminated
prematurely because of the surgical staff change. A larger multi-
centre study should be considered to validate a FIBTEM MCF of
13 mm as a potential haemostatic target to reduce allogeneic
blood exposure, postoperative intensive care stay, and other
transfusion-related complications.
Besides the limitations of a small single-centre study, the
study of Haas and colleagues15 is underpowered for any safety
analysis. Overdosing of ﬁbrinogen concentrate might be asso-
ciated with thromboembolic complications, especially in pa-
tients with cardiovascular diseases.25 26 There is a paucity of
data on the safety of any factor concentrate usage in paediatric
acquired coagulopathy, but the thromboembolic risk of paediat-
ric patients appears to be lower than that of adults.27 In adult car-
diac surgery, the administration of ﬁbrinogen targeting a plasma
concentration of ∼2 g litre−1 (corresponding to a FIBTEM MCF of
∼10mm)was not associatedwithworse 30 dayand 1 yr outcomes
compared with patients without administration of ﬁbrinogen
concentrate.4
In summary, the work of Haas and colleagues15 has provided
further evidence thatmaintaining ﬁbrinogen at above 2.0 g litre−1
might be more advantageous in reducing bleeding volumes and
red blood cell transfusion than on-demand therapy after ﬁbrino-
gen concentration reduces to below 1.5 g litre−1. The extrapola-
tion of their ﬁndings to general paediatric surgical populations
should be done cautiously, because this was a single-centre
study with a limited sample size in very speciﬁc surgical proce-
dures. At present, a routine prophylactic administration of ﬁ-
brinogen concentrate is not recommended, but a ﬁbrinogen
concentration below 2.0 g litre−1 or FIBTEM MCF below 10 mm
seems to be an acceptable target to commence early haemostatic
intervention in patients who are at increased risk for profuse
bleeding in major surgery.
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Sir Muir Gray, Director of the NHS Chief Knowledge Ofﬁce, hy-
pothesized that ‘The application of what we know will have a
bigger impact than any drug or technology likely to be introduced
in the next decade.’ He recognized that blind investment in new
drugs and technologies that provide only amodest improvement
in efﬁcacy may cost more lives than it saves, because this invest-
ment will consume scarce resources needed for improved deliv-
ery of care. Therefore, it can be argued from a health, economic,
andmoral standpoint that we should spend less on new technol-
ogy and new drugs and more on improving systems for delivery
of care1 and turning knowledge into action.
Whilst few of us would disagree that robust evidence from
clinical trials should be implemented to improve patient care, it
has become apparent that a gap exists and that the translation
of evidence into routine practice is not as widespread and easily
done as onewould have expected. Evidence suggests that it takes
on average 17 years for research evidence to reach clinical prac-
tice.2 This is a remarkably slow and inefﬁcient process. Indeed,
it took 13 years for cardiologists to recommend thrombolysis for
the treatment of acutemyocardial infarction after the publication
of randomized controlled trials showed therapeutic beneﬁt.3 Fur-
thermore, Lomas and colleagues4 calculated a 5 year gap between
publication of guidelines and changes to routine practice in
Western health-care systems. Although the paucity of robust
andhigh-quality evidence in critical care used to be cited as a rea-
son for the lack of change in practice, critical care research in the
last 10 years has been inundatedwith a number of practice-chan-
ging headlines, leaving clinicians with the responsibility of en-
suring that these are incorporated into everyday practice to
enable patients to receive safe, effective, and person-centred
care.
In 2000, the acute respiratory distress syndrome (ARDS) net-
work study demonstrated conclusively and unarguably that lim-
iting tidal volume to <6ml kg−1 predicted body weight (PBW) and
end-inspiratory pressure to not more than 30 cm H2O, compared
with patients ventilated with higher tidal volumes (>12 ml kg−1
PBW), signiﬁcantly reduces mortality in acute lung injury and
ARDS, with a number needed to treat of 11 patients to save one
life.5 No special equipment or expertise was required to achieve
this beneﬁt. Despite the perceived relative simplicity of imple-
menting low-tidal volume ventilation, a number of studies pub-
lished in the last 10 years reveal a disappointing failure of
clinicians to adopt and implement this piece of evidence.6–8
In a simple yet elegantly designed and conducted service
evaluation study in this issue of the BJA, Bourdeaux and collea-
gues9 have demonstrated how a large screen conﬁgured to dis-
play information routinely collected from a clinical information
system resulted in a signiﬁcant and sustained improvement in
the use of evidence-based ventilation practice and reduced un-
warranted tidal volume variation with improved reliability. In a
mixed medical and surgical intesive care unit in a UK teaching
hospital, two similar cohorts of patients on controlledmechanical
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